Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289723 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Anam Tariq und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Government College University Faisalabad (GCUF), Faisalabad, Pakistan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tandem Mass Spectrometry. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Higher Education Commision, Pakistan.
Abstract (Originalsprache)
Lactic acid bacteria are known to produce numerous antibacterial metabolites that are active against various pathogenic microbes. In this study, bioactive metabolites from the cell free supernatant of Loigolactobacillus coryniformis BCH-4 were obtained by liquid-liquid extraction, using ethyl acetate, followed by fractionation, using silica gel column chromatography. The collected F23 fraction effectively inhibited the growth of pathogenic bacteria ( Escherichia coli , Bacillus cereus , and Staphylococcus aureus ) by observing the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC). The evaluated values of MIC were 15.6 ± 0.34, 3.9 ± 0.59, and 31.2 ± 0.67 μg/mL and MBC were 15.6 ± 0.98, 7.8 ± 0.45, and 62.5 ± 0.23 μg/mL respectively, against the above-mentioned pathogenic bacteria. The concentration of F23 fraction was varying from 1000 to 1.9 μg/mL. Furthermore, the fraction also exhibited sustainable biofilm inhibition. Using the Electrospray Ionization Mass Spectrometry (ESI-MS/MS), the metabolites present in the bioactive fraction (F23), were identified as phthalic acid, myristic acid, mangiferin, 16-hydroxylpalmatic acid, apigenin, and oleandomycin. By using in silico approach, docking analysis showed good interaction of identified metabolites and receptor proteins of pathogenic bacteria. The present study suggested Loigolactobacillus coryniformis BCH-4, as a promising source of natural bioactive metabolites which may receive great benefit as potential sources of drugs in the pharmacological sector.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.
- National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan.
- Department of Applied Chemistry, Government College University Faisalabad (GCUF), Faisalabad, Pakistan.
- Industrial Biotechnology Division, National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C,PIEAS), Faisalabad, Pakistan.
ORCID-Profile: Mahwish Salman, Ghulam Mustafa, Abdul Tawab, Misbah Shahid
Förderung
- Higher Education Commision, Pakistan
Zitieren
APA
Tariq, A., Salman, M., Mustafa, G., Tawab, A., Naheed, S., Naz, H., Shahid, M., & Ali, H. (2023). Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach. PLOS ONE. https://doi.org/10.1371/journal.pone.0289723
Vancouver
Tariq A, Salman M, Mustafa G, Tawab A, Naheed S, Naz H, et al. Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach. PLOS ONE. 2023. doi:10.1371/journal.pone.0289723
BibTeX
@article{Tariq2023,
author = {Tariq, Anam and Salman, Mahwish and Mustafa, Ghulam and Tawab, Abdul and Naheed, Shazia and Naz, Hafsa and Shahid, Misbah and Ali, Hazrat},
title = {Agonistic antibacterial potential of Loigolactobacillus coryniformis BCH-4 metabolites against selected human pathogenic bacteria: An in vitro and in silico approach},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289723}
}
EUVIMED